TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00860522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JVRS-100
Description: Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JVRS-100
Description: Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
Study: NCT04273854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMRON Evolv® blood pressure monitor (Blue-tooth® enabled) & Proprietary Smartphone POP-HT app®
Description: The intervention will consist of physician-optimised self-management of post-partum BP. Women will follow a 'smartphone' app based algorithm for medication-titration, which will provide individualised dose titration advice. This is overseen and any change is approved by physicians who can review the uploaded readings and respond to tele-monitored abnormal readings in a timely fashion.
Study: NCT04430894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: * Induction: protocol determine dose,via IV on 3 days per cycle up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination~* Maintenance: protocol determine dose,via IV on 2 days per cycle- Maintenance Cycle until progressive disease (PD) or unacceptable toxicity
Study: NCT03470896

Intervention type: PROCEDURE
Group type: OTHER
Intervention: preanesthesia traditional consultation
Description: According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preanesthesia traditional consultation
Description: According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
Study: NCT03782688

Intervention type: DIAGNOSTIC_TEST
Intervention: FFRCT planner
Description: Non-invasive post-PCI fractional flow reserve prediction
Study: NCT03556046

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-Girentuximab
Description: Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
Study: NCT06596382

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol rich-vitamin E
Description: Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Tocotrienol rich-vitamin E
Description: Two dosage are available which are 100 mg for NAFLD patient with underlying metabolic syndrome meanwhile 50mg for NALFD patient without metabolic syndrome

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replicate for tocotrienol rich-vitamin E without any active ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Replicate for tocotrienol rich-vitamin E without any active ingredients
Study: NCT02069145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-54F28 with Sorafenib
Study: NCT00424632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03814735
Description: 1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
Study: NCT04130594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac
Description: a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac
Description: a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac
Description: a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00018174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral group smoking cessation treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral group smoking cessation treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01827072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-01
Study: NCT04223856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion on Day 1 of every 3-week cycle
Study: NCT03312881

Intervention type: DIAGNOSTIC_TEST
Intervention: quantitative sensory testing
Description: multiple modality testing of generalized and localized changes in somatosensory perception

Intervention type: DIAGNOSTIC_TEST
Intervention: neuroimaging
Description: magnetic resonance imaging (MRI)

Intervention type: OTHER
Intervention: Patient Reported Outcome Measures
Description: neuropathic pain screening tool; validated questionnaires

Intervention type: OTHER
Intervention: Patient Reported Outcome Measures
Description: neuropathic pain screening tool; validated questionnaires
Study: NCT02384239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given by intramuscular (IM) injection.
Study: NCT04223856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: administered as IV infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Dosed according to local guidelines and will be administered as IV infusion on Day 1 of each 3-week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion on Days 1 and 8 of every 3 week cycle
Study: NCT03492307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)
Description: A weight-based flow for HFNC.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Flow for HFNC (Maximum 8L/minute)
Description: Maximum flow of 8L/minute.
Study: NCT03910335

Intervention type: DIAGNOSTIC_TEST
Intervention: LSS Screen
Description: Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)

Intervention type: DIAGNOSTIC_TEST
Intervention: LSS Screen
Description: Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
Study: NCT04585334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricortin 1000
Description: Tricortin 1000 \[2 mL ampoules containing 12 mg of phospholipids and 1 mg of Vitamin B12 (Cyanocobalamin)\] will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itami
Description: Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications plus Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
Study: NCT00938925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nail lacquer plus aggressive debridement
Description: Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nail lacquer alone
Description: Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
Study: NCT03886038

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shingrix
Description: immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
Study: NCT04430894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: * Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  -- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: * Induction: At predetermined dose, via IV up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination:~  -- Cycles 1 and 2 once per week, Cycles 3-4 every other week, Cycles 5 and 6 every other week, Cycles 7 and 8 once every 4 weeks.~* Maintenance: At predetermined dose, via IV, once per cycle, Maintenance Cycle until progressive disease (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: - Induction Predetermined Dose, oral, days 1-21 of up to 8 cycles, dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: At predetermined dose, oral days 1-21 per cycle until progressive disease (PD) or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Induction: Predetermined dosage, oral, Predetermined times per cycle up to 8 cycles dependent on Upfront Stem Transplant or Deferring Stem Cell Transplant determination Maintenance: orally or IV will be administered as a preinfusion medication prior to isatuximab dosing
Study: NCT02397902

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat dairy
Description: Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based
Description: Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
Study: NCT04578691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anatase Spine Surgery Navigation System
Description: using navigation system in pedicle screw placement in spine surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Stealthstation S7 Treatment Guidance System
Description: using navigation system in pedicle screw placement in spine surgery
Study: NCT01328223

Intervention type: RADIATION
Intervention: sorafenib and radiotherapy for hepatocellular carcinoma
Description: Concurrent and maintenance sorafenib 400mg twice daily
Study: NCT02275351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04554
Description: Topical solution, applied once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM04554
Description: Topical solution, applied once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical solution, applied once a day
Study: NCT02001467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation-based training
Study: NCT02033889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin \>=1500 mg/day, orally, once a day
Study: NCT02384239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given by intramuscular (IM) injection.
Study: NCT01500434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMUS Element Coronary Stent System
Description: PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thienopyridine
Description: Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
Study: NCT01446302

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Double meal
Description: A standardized meal is served 1 h after start of HD and 1 h after end of HD.
Study: NCT02500589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral mood management
Description: The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.

Intervention type: OTHER
Group type: OTHER
Intervention: Health education
Description: In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information.
Study: NCT01881477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kinetics modalities
Description: The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk.
Study: NCT02033889

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin \>=1500 mg/day, orally, once a day
Study: NCT00623220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: N2O
Description: EMONO
Study: NCT03808181

Intervention type: DEVICE
Group type: OTHER
Intervention: ChloraSolv
Description: Weekly application of ChloraSolv for 6 weeks
Study: NCT00852059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release methylphenidate (Medikinet®)
Description: Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release methylphenidate (Medikinet retard®)
Description: Treatment: methylphenidate applied with breakfast(once daily), extended release
Study: NCT00623220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Description: oxygen
Study: NCT02569697

Intervention type: OTHER
Group type: OTHER
Intervention: HEC Placebo gel
Study: NCT01874028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trientine dihydrochloride
Description: Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
Study: NCT01953302

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified open mesh technique
Description: We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
Study: NCT02569697

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Intravaginal Ring

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Film
Study: NCT00323375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ-13
Description: A treatment dose of AQ-13 (1750 mg base) was administered orally to subjects randomized to AQ-13 over 3 days (as two capsules on days 1 and 2, plus one capsule on day 3).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine (CQ) Treatment
Description: A treatment dose of CQ (1500 mg CQ base) was administered orally to subjects randomized to CQ over 3 days (as two capsules on days 1 and 2, and one capsule on day 3).
Study: NCT02569697

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Vaginal Insert
Study: NCT01353339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 500mg, PO, once daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin
Description: 500mg, PO, once daily for 3 months
Study: NCT01031329

Intervention type: PROCEDURE
Intervention: Tympanocenthesis and urine collection
Description: Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
Study: NCT04283240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 50 mg sildenafil, one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02824055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
Study: NCT04286035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Femoral nerve block with 20 ml %0.375 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Injection
Description: Adductor canal block with 20 ml %0.375 bupivacaine